Key facts
as of Sep 2026- Watershed Therapeutics’s last known valuation is $24.9M (Feb 2026).
- It has raised $9.0M; the latest was Equity Crowdfunding ($870K) in Feb 2026.
- Notable investors include WTIA Startup Program, Lateral Capital Management, WRF Capital, 4i Ventures, Alliance of Angels — 10 tracked in total.
- 4 institutional filers report fund marks on Watershed Therapeutics across 6 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Watershed Therapeutics
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Watershed Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
4 filers · latest May 20264 SEC-registered funds reported 6 fair-value marks on Watershed Therapeutics between Jun 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Watershed Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Watershed Therapeutics
Developer of a targeted drug delivery technology designed to deliver long-term therapies directly to the bladder with minimal procedures and improved patient comfort. The company offers localized delivery systems for the prevention of bladder cancer, overactive bladder, and recurrent urinary tract conditions, enabling urologists and patients to achieve sustained treatment effectiveness with reduced procedural burden.
- Sector
- Healthcare
- HQ
- Bellevue, WA, United States
- Founded
- 2019
- Employees
- 10
- Website
- watershedtx.com/
- Ownership
- Privately Held (backing)